Bitopertin Expanded Access

CAP has learned that Disc Medicine may be able to provide an Expanded Access Program in Canada for Bitopertin. This program is intended for people ages 12 and older living with EPP or XLP. An EAP allows certain patients to access an investigational treatment outside of a clinical trial, provided they meet specific eligibility criteria.

The program is not yet open.

Because details are still being finalized, available information is limited at this time. To help us understand community interest, and to ensure we can share updates as soon as they are available, including study sites and inclusion criteria, we invite you to complete the interest form below.

Please note that submitting the form does not enroll you in the program or guarantee access to bitopertin.

Bitopertin remains an investigational medicine. It has not been approved by any regulatory authority, and its safety and effectiveness have not yet been established.

We will continue to share updates as more information becomes available.